Cold plasma selectivity and the possibility of a paradigm shift in cancer therapy

721Citations
Citations of this article
370Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: Plasma is an ionised gas that is typically generated in high-temperature laboratory conditions. However, recent progress in atmospheric plasmas has led to the creation of cold plasmas with ion temperature close to room temperature. Methods: Both in-vitro and in-vivo studies revealed that cold plasmas selectively kill cancer cells. Results: We show that: (a) cold plasma application selectively eradicates cancer cells in vitro without damaging normal cells; and (b) significantly reduces tumour size in vivo. It is shown that reactive oxygen species metabolism and oxidative stress responsive genes are deregulated. Conclusion: The development of cold plasma tumour ablation has the potential of shifting the current paradigm of cancer treatment and enabling the transformation of cancer treatment technologies by utilisation of another state of matter. © 2011 Cancer Research UK All rights reserved.

Cite

CITATION STYLE

APA

Keidar, M., Walk, R., Shashurin, A., Srinivasan, P., Sandler, A., Dasgupta, S., … Trink, B. (2011). Cold plasma selectivity and the possibility of a paradigm shift in cancer therapy. British Journal of Cancer, 105(9), 1295–1301. https://doi.org/10.1038/bjc.2011.386

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free